Extraintestinale Manifestationen

Definition extraintestinaler Manifestationen bei Morbus Crohn

Konsens

Erkrankungen außerhalb des GI-Traktes bei Patienten mit Morbus Crohn, bei denen aufgrund der klinischen Assoziation oder pathogenetischer Mechanismen ein Zusammenhang mit der entzündlichen Darmerkrankung besteht oder vermutet werden muss (B).

Hiervon werden extraintestinale Begleiterkrankungen (Gallensteine, Nierensteine) und nicht krankheitsspezifische Komplikationen (Amyloidose, Osteoporose, thromboembolische Komplikationen) abgegrenzt (B).

Literatur

• 1 Orchard T R, Wordsworth B P, Jewell D P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history.  Gut. 1998;  42 387-391 (III)
• 2 Greenstein A J, Janowitz H D, Sachar D B. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients.  Medicine (Baltimore). 1976;  55 401-412 (III)
• 3 Gran J T, Husby G. Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn’s disease.  Digest Dis. 1992;  10 274-294 (III)
• 4 de Vlam K, Mielants H, Cuvelier C. et al . Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association.  J Rheumatol. 2000;  27 2860-2865 (III)
• 5 Protzer U, Duchmann R, Hohler T. et al . Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association.  Med Klin. 1996;  91 330-335 (III)
• 6 Braun J, Bollow M, Remlinger G A. et al . Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.  Arthritis Rheum. 1998;  41 58-67 (III)
• 7 Scott W W Jr, Fishman E K, Kuhlman J E. et al . Computed tomography evaluation of the sacroiliac joints in Crohn disease. Radiologic/clinical correlation.  Skeletal Radiol. 1990;  19 207-220 (III)
• 8 Stein H, Volpin G, Shapira D. et al . Musculoskeletal manifestations of Crohn’s disease.  Bull Hosp Jt Dis. 1993;  53 17-20 (III)
• 9 Ferraz M B, Tugwell P, Goldsmith C H. et al . Meta-analysis of sulfasalazine in ankylosing spondylitis.  J Rheumatol. 1990;  17 1482-1486 (Ia)
• 10 Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients.  Br Med J (Clin Res Ed). 1986;  293 911-914 (Ib)
• 11 Dougados M, vam d er Linden S, Leirisalo-Repo M. et al . Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study.  Arthritis Rheum. 1995;  38 618-627 (Ib)
• 12 Mielants H, Veys E M. HLA-B27 related arthritis and bowel inflammation. Part 1. Sulfasalazine (salazopyrin) in HLA-B27 related reactive arthritis.  J Rheumatol. 1985;  12 287-293 (III)
• 13 Dougados M, Maetzel A, Mijiyawa M. et al . Evaluation of sulphasalazine in the treatment of spondyloarthropathies.  Ann Rheum Dis. 1992;  51 955-958 (III)
• 14 Thomson G T, Thomson B R, Thomson K S. et al . Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies.  J Rheumatol. 2000;  27 714-718 (III)
• 15 Florin T H, Graffner H, Nilsson L G. et al . Treatment of joint pain in Crohn’s patients with budesonide controlled ileal release.  Clin Exp Pharmacol Physiol. 2000;  27 295-298 (III)
• 16 Brandt J, Haibel H, Cornely D. et al . Successful treatment of active ankylosing spondylitis with the anti- tumor necrosis factor alpha monoclonal antibody infliximab.  Arthritis Rheum. 2000;  43 1346-1352 (III)
• 17 Van den Bosch F, Kruithof E. et al . Crohn’s disease associated with spondyloarthropathy: effect of TNF- alpha blockade with infliximab on articular symptoms.  Lancet. 2000;  356 1821-1822 (III)
• 18 Felder J B, Korelitz B I, Rajapakse R. et al . Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study.  Am J Gastroenterol. 2000;  95 1949-1954 (III)
• 19 Evans J M, McMahon A D, Murray F E. et al . Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease.  Gut. 1997;  40 619-622 (III)
• 20 Bonner G F, Walczak M, Kitchen L. et al . Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease.  Am J Gastroenterol. 2000;  95 1946-1948 (III)
• 21 Rasmussen H H, Fallingborg J E, Mortensen P B, Vyberg M, Tage-Jensen U, Rasmussen S N. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn ‘s disease.  Scand J Gastroenterol. 1979;  32 604-610 (III)
• 22 Bernstein C N, Blanchard J F, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study.  Am J Gastroenterol. 2001;  96 1116-1122 (IIb)
• 23 Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B. Primary sclerosing cholangitis in patients with chronic inflammatory bowel disease in Turkey.  J Clin Gastroenterol. 2001;  33 299-301 (III)
• 24 Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann W J, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo controlled study period.  J Hepatol. 1994;  20 57-64 (Ib)
• 25 Stiehl A, Rudolph G, Sauer P. et al . Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis.  J Hepatol. 1997;  26 560-566 (Ib)
• 26 Mitchell S A, Bansi D S, Hunt N, von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907 (Ib)
• 27 Lee J G, Schutz S M, England R E, Leung J W, Cotton P B. Endoscopic therapy of sclerosing cholangitis.  Hepatology. 1995;  21 661-667 (Ib)
• 28 Harnois D M, Angulo P, Jorgensen R A, Larusso N F, Lindor K D. High-dose ursodeoxycholic acid as a therapy für patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2001;  96 1558-1562 (Ib)
• 29 Broomé U, Olsson R, Loof L. et al . Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.  Gut. 1996;  38 610-615 (III)
• 30 Heathcote J. Autoimmune cholangitis and overlap syndromes. In: Diseases of the bile duct: Pathogenesis, pathology and practice.  Postgraduate course of the American Association for Study of the Liver Diseases. 1996;  121-131 (III)
• 31 Gregory B, Ho V C. Cutaneous manifestations of gastrointestinal disorders. Part II.  J Am Acad Dermatol. 1992;  26 371-383 (III)
• 32 Kirsch B, Gerhardt H, Gladisch R. et al . Dermatosen bei chronisch entzündlichen Darmerkrankungen. Ergebnisse einer Untersuchung von 119 M.-Crohn-/C.-ulcerosa-Patienten.  Akt Dermatol. 1992;  18 17-22 (III)
• 33 Blitz N M, Rudikoff D. Pyoderma gangrenosum.  Mount Sinai J Med. 2001;  68 287-297 (III)
• 34 Tromm A, May D, Almus E. et al . Cutaneous manifestations in inflammatory bowel disease.  Z Gastroenterol. 2001;  39 137-144 (III)
• 35 Latkany P A, Jabs D A. Ocular manifestations of inflammatory bowel disease. Bayless TM, Hanauer SB Advanced therapy of inflammatory bowel disease London; B.C. Decker 2001: 275-277 (III)
• 36 Soukiasian S H, Foster C S, Raizman M B. Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease.  Am J Ophthalmol. 1994;  118 601-611 (IIb)
• 37 Rickli H, Fretz C, Hoffman M. et al . Severe inflammatory upper airway stenosis in ulcerative colitis.  Eur Respir J. 1994;  7 1899-1902 (III)
• 38 Munck A, Murciano D, Pariente R. et al . Latent pulmonary function abnormalities in children with Crohn’s disease.  Eur Respir J. 1995;  8 377-381 (III)
• 39 Camus P, Piard F, Ashcroft T. et al . The lung in inflammatory bowel disease.  Medicine. 1993;  72 151-83 (III)
• 40 Mahadeva R, Walsh G, Flower C D. et al . Clinical and radiological characteristics of lung disease in inflammatory bowel disease.  Eur Respir J. 2000;  15 41-48 (III)
• 41 Tromm A, Höltmann B, Hüppe D. et al . Hyperamylasämie, Hyperlipasämie und akute Pankreatitiden bei chronisch entzündlichen Darmerkrankungen.  Leber Magen Darm. 1991;  1 15-22 (III)
• 42 Niemelä S, Lehtola J, Karttunen T. et al . Pancreatitis in patients with chronic inflamatory bowel disease.  Hepatogastroenterol. 1989;  36 175-177 (III)
• 43 Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn’s disease.  J Clin Gastroenterol. 1993;  17 286-291 (III)
• 44 Rasmussen H H, Fonager K, Sorensen H AT. et al . Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study.  Scand J Gastroenterol. 1999;  34 199-201 (III)
• 45 Spiess S E, Braun M, Vogelzang R L. et al . Crohn’s disease of the duodenum complicated by pancreatitis and common bile duct obstruction.  Am J Gastroenterol. 1992;  87 1033-1036 (IV)
• 46 Herrlinger K R, Stange E F. The pancreas and inflammatory bowel disease.  Int J Pancreatol. 2001;  27 171-179 (IV)
• 47 Heikius B, Niemela S, Lehtola J. et al . Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease.  Am J Gastroenterol. 1999;  94 1062-1069 (IIb)
• 48 Katz S, Bank S, Greenberg R E. et al . Hyperamylasemia in inflammatory bowel disease.  J Clin Gastroenterol. 1988;  10 627-630 (III)
• 49 Heikius B, Niemelä S, Lehtola J. et al . Pancreatic duct abnormalities and pancreatic function in patients with chronic inflammatory bowel disease.  Scand J Gastroenterol. 1996;  31 517-523 (IIb)
• 50 Heikius B, Niemelä S, Lehtola J. et al . Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease.  Scand J Gastroenterol. 1997;  32 153-161 (IIb)
• 51 Seibold F, Mork H, Tanza S. et al . Pancreatic autoantibodies in Crohn’s disease: a family study.  GUT. 1997;  40 481-484 (IIb)
• 52 Herrlinger K R, Noftz M K, Fellermann K, Schmidt K, Steinhoff J, Stange E F. Minimal renal dysfunction in inflammtory bowel disease is related to disease activity but not to 5-ASA use.  Aliment Pharm Therap. 2001;  15 363-369 (IIb)
• 53 Kreisel W, Wolf L M, Grotz W, Grieshaber M. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.  Eur J Gastroenterol Hepatol. 1996;  8 461-468 (III)
• 54 Lossos A Y, River A, Steiner E. et al . Neurologic aspects of inflammatory bowel disease.  Neurology. 1995;  45 416-421 (III)
• 55 Brohee P, Violon P, Mavroudakis N. et al . Central nervous system lesions associated with Crohn’s disease.  J Neuroimaging. 1997;  7 195-198
• 56 Geissler A, Andus T, Roth M. et al . Focal white-matter lesions in brain of patients with inflammatory bowel disease.  Lancet. 1995;  345 897-898 (III)
• 57 Wakefield A J, Sawyerr A M, Dhillon A P. et al . Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction.  Lancet. 1989;  2 1057-1062
• 58 Wakefield A J, Sankey E A, Dhillon A P. et al . Granulomatous vasculitis in Crohn’s disease.  Gastroenterology. 1991;  100 1279-1287
• 59 Talbot R W, Heppell J, Dozois R R. et al . Vascular complications of inflammatory bowel disease.  Mayo Clin Proc. 1986;  61 140-145 (III)
• 60 Bernstein C N, Blanchard J F, Houston D S. et al . The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.  Thromb Haemost. 2001;  83 430-434 (IIb)
• 61 Koutroubakis I E. Role of thrombotic vascular risk factors in inflammatory bowel disease.  Digest Dis. 2000;  18 161-167 (IIb)
• 62 Jackson L M, O’Gorman P J, O’Connell J. et al . Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden.  QJM. 1997;  90 183-188 (IIb)
• 63 Lapidus A, Bangstad M, Astrom M, Muhrbeck O. The prevalence of gallstone disease in a defined cohort of patients with Crohn’s disease.  Am J Gastroenterol. 1999;  94 1261-1266 (Ib)
• 64 Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn’s disease.  Inflammatory Bowel Diseases. 1998;  4 89-94 (IIa)
• 65 Brink M A. et al . Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn’s disease.  Gastroenterology. 1999;  116 1420-1427 (IIa)
• 66 Hylander E, Jarnum S, Jensen H J, Thale M. Enteric hyperoxaluria:dependence on small intestinal resection, colectomy, and steatorrhoea in chronic inflammatory bowel disease.  Scand J Gastroenterol. 1978;  13 577-588 (IIb)
• 67 Stelzner M, Philips J D, Saleh S, Fonkalsrud E W. Nephrolithiasis and urine ion changes in ulcerative colitis undergoing colectomy and endorectal ileal pullthrough.  J Surg Res. 1990;  48 552-556 (III)
• 68 Chadwick V S, Modha K, Dowling R H. Mechanism for hyperoxaluria in patients with ileal dysfunction.  N Engl J Med. 1973;  289 172 (III)
• 69 Bohles H, Beifuss O J, Brandl U, Pichl J, Akcetin Z, Demling L. Urinary factors of kidney stone formation in patients with Crohn's disease.  Klin Wochenschr. 1988;  66 87-91 (III)
• 70 Manganiotis A N, Banner M P, Malkowicz S B. Urologic complications of Crohn's disease.  Surg Clin North Am. 2001;  81 197-215 (III)
• 71 Sato S, Sasaki I, Naito H. et al . Management of urinary complications in Crohn's disease.  Surg Today. 1999;  29 713-717 (III)
• 72 McLeod R S, Churchill D N. Urolithiasis complicating inflammatory bowel disease.  J Uro. 1992;  148 979 (III)
• 73 Kleinhans G, Leusmann D, Pohl J, Pott G. Urologische Komplikationen bei 200 Patienten mit Morbus Crohn.  Z Gastroenterol. 1985;  23 362-374 (III)
• 74 Fukushima T, Sugita A, Masuzawa S, Yamazaki Y, Takemura H, Tsuchiya S. Prevention of uric acid stone formation by sodium bicarbonate in an ileostomy patient - a case report.  Jpn J Surg. 1988;  18 165-168 (III)
• 75 D’Cruz D P, Gertner D J, Kasidas G P, Rampton D S, Rose G A, Samuell C T. Failure of allopurinol to modify urinary composition in enteric hyperoxaluria.  Br J Urol. 1989;  64 231-234 (IIb)
• 76 Bernstein C N, Seeger L L, Sayre J W. et al . Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis.  J Bone Miner Res. 1995;  10 250-256 (III)
• 77 Ardizzone S, Bollani S, Bettica P. et al . Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis.  J Intern Med. 2000;  247 63-70 (III)
• 78 Silvennoinen J A, Karttunen T J, Niemela S E. et al . A controlled study of bone mineral density in patients with inflammatory bowel disease.  Gut. 1995;  37 71-76 (III)
• 79 von Tirpitz C, Pischulti G, Rieber A. et al . Pathologische Knochendichte bei chronisch entzündlichen Darmerkrankungen - Prävalenz und Risikofaktoren.  Z Gastroenterologie. 1999;  37 5-12 (III)
• 80 Clements D, Motley R J, Evans W D. et al . Longitudinal study of cortical bone loss in patients with inflammatory bowel disease.  Scand J Gastroenterol. 1992;  27 1055-1060 (III)
• 81 Andreassen H, Rungby J, Dahlerup J F. Inflammatory bowel disease and osteoporosis.  Scand J Gastroenterol. 1997;  32 1247-1255 (III)
• 82 Silvennoinen J A, Lehtola J K, Niemela S E. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease.  Scand J Gastroenterol. 1996;  31 367-371 (IIb)
• 83 von Tirpitz C, Kohn C, Steinkamp M. et al . Lactose intolerance in active Crohn’s disease.  J Clin Gastroenterol. 2002;  34 49-53 (IIb)
• 84 Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.  BMJ. 1996;  312 1254-1259 (Ia)
• 85 Klaus J, Armbrecht G, Steinkamp M. et al . High prevalence of osteoporotic vertebral fractures in patients with Crohn’s disease.  Gut. 2002;  51 654-688 (IIb)
• 86 Vestergaard P, Krogh K, Rejnmark L. et al . Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis.  Gut. 2000;  46 176-181 (IIb)
• 87 Bernstein C N, Blanchard J F, Leslie W. et al . The Incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study.  Ann Intern Med. 2000;  133 795-799 (IIb)
• 88 Vogelsang H, Ferenci P, Resch H. et al . Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation.  Eur J Gastroenterol Hepatol. 1995;  7 609-614 (Ib)
• 89 von Tirpitz C, Klaus K, Brückel J. et al . Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease.  Eur J Gastroenterol Hepatol. 2000;  11 19-24 (Ib)
• 90 Adachi J D, Bensen W G, Bianchi F. et al . Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year follow up.  J Rheumatol. 1996;  23 995-1000 (Ib)
• 91 Buckley L M, Leib E S, Cartularo K S. et al . Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1996;  125 961-968 (Ib)
• 92 Clements D, Compston J E, Evans W D. et al . Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.  Gut. 1993;  34 1543-1546 (Ib)
• 93 Haderslev K V, Tjellesen L, Sorensen H A. et al . Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease.  Gastroenterology. 2000;  119 639-646 (Ib)
• 94 Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss.  Br J Rheumatol. 1994;  33 348-350 (Ib)
• 95 Roux C, Oriente P, Laan R. et al . Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.  J Clin Endocrinol Metab. 1998;  83 1128-1133 (Ib)
• 96 Adachi J D, Bensen W G, Brown J. et al . Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.  N Engl J Med. 1997;  337 382-387 (Ib)
• 97 Lems W F, Jacobs W G, Bijlsma J W. et al . Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis.  Osteoporos Int. 1997;  7 575-582 (Ib)
• 98 Pak C Y, Sakhaee K, Adams H uet B. et al . Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial.  Ann Intern Med. 1995;  123 401-408 (Ib)
• 99 Riggs B L, Hodgson S F, O’Fallon W M. et al . Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.  N Engl J Med. 1990;  322 802-809 (Ib)
• 100 Greenstein A J, Sachar D B, Panday A K. et al . Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients.  Medicine. 1992;  71 261-270 (III)
• 101 Wester A L, Vatn M H, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998.  Inflamm Bowel Dis. 2001;  7 295-300 (III)